Guest Editors
Assoc. Prof. Anton Tkachenko
Email: anton.tkachenko@lf1.cuni.cz
Affiliation: BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic
Homepage:
Research Interests: apoptosis, cell signaling, ferroptosis, nanotoxicity, regulated cell death
Assoc. Prof. Volodymyr Prokopiuk
Email: v.yu.prokopiuk@gmail.com
Affiliation: Department of Cryobiochemistry, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine
Homepage:
Research Interests: apoptosis, eryptosis, cell death, cell signaling
Summary
Over the recent years, a wide spectrum of regulated cell death (RCD) pathways (apoptosis, ferroptosis, necroptosis, pyroptosis, PANoptosis, disulfidptosis, parthanatos, cuproptosis, autophagy-dependent cell death, methuosis, etc.) have emerged as a potential target for anti-cancer therapy. In addition to direct malignant cell-killing properties, RCD targeting can affect anti-tumor immunity, exploit tumor vulnerabilities, including for tailoring a personalized treatment, overcome multi-drug resistance, and amplify the effect of conventional therapeutic strategies. Compelling evidence indicates that nanomaterials are promising modulators of RCDs. At the same time, although the field is rapidly developing and a plethora of RCD-modulating nanomaterials are under investigation, clinical translation of nanomedicines remains insufficient. This Special Issue aims to shed more light on the role (often contradictory and Janus-faced) of distinct RCDs in carcinogenesis and tumor progression and underscore the recent advances in RCD targeting with nanomaterials as an anti-cancer therapeutic avenue.
Keywords
apoptosis, ferroptosis, necroptosis, pyroptosis, regulated cell death
Login
Register
Submit a Paper
Propose a Special lssue